Adam Sperling, MD, PhD, Dana-Farber Cancer Institute, Boston, MA, shares some insights into the role of clonal hematopoiesis (CH) in multiple myeloma and how this may impact treatment approaches for patients. This interview took place at the 20th International Myeloma Society (IMS) Annual Meeting, held in Athens, Greece.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.